Injectable Platelet Rich Fibrin Versus Platelet Rich Plasma Injection in Degenerative Temporomandibular Joint

Nasser Institute For Research and Treatment20 enrolled

Overview

The study aimed to compare the efficacy of injectable platelet rich fibrin (I-PRF) versus platelet rich plasma (PRP) injection in degenerative temporomandibular joint (TMJ).

Degenerative joint disease (DJD), a frequently observed as osteoarthritic condition in clinical practice, manifests as a persistent and continuous transformation in joint configuration due to the deterioration and attrition of articular cartilage, accompanied by modifications in the subchondral bone and other soft tissue. Treatment includes physical therapy, pulsed electrical stimulation, pharmacological, topical ointments, supplements, steroid injections, hyaluronic acid (HA) injections, and acupuncture. Further studies have been carried out to better investigate the effectiveness of different techniques to perform arthrocentesis by using growth factors, autologous solutions, or alternative materials; the materials most used are platelet-rich plasma (PRP) and HA in arthrocentesis or by injection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Platelet Rich Fibrin Platelet Rich Plasma Injection Degenerative Temporomandibular Joint

Interventions

Platelet Rich FibrinOTHER

Patients underwent arthrocentesis followed by a platelet-rich fibrin (PRF) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.

Platelet Rich PlasmaOTHER

Patients underwent arthrocentesis followed by a platelet-rich plasma (PRP) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>18 years old. * Both sexes. * Patients with unilateral or bilateral temporomandibular joint (TMJ) osteoarthritis according to magnetic resonance imaging (MRI) evaluation. Exclusion Criteria: * Patients under any type of antiplatelet or anticoagulant medications. * Cardiovascular, renal, or hepatic disease. * Diabetes. * Anemia. * Vascular insufficiency. * Peripheral neuropathy. * Previous surgery for TMJ and rheumatoid arthritis.

Locations (1)

Nasser

Cairo, Egypt

Outcomes

Primary Outcomes

Pain improvement

Each patient will be instructed about postoperative pain assessment with the Visual Analogue Scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). VAS was recorded preoperatively, immediately after the procedures, 1 month, 3 months, and 6 months postoperatively.

Time frame: 6 months post-procedure

Secondary Outcomes

Assessment of tissue repair

Tissue repair in the form of initiating fibrin coating around the osteoarthritic joint by using Magnetic Resonance Imaging (MRI) was recorded.

Time frame: 6 months post-procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.